The trend of the high boom track has been sluggish recently. Among them, Porton Pharma Solutions Ltd(300363) the leading stock of the innovative drug branch with a total market value of more than 30 billion has experienced the largest cumulative decline of more than 40% since the peak in August 2021.
After hours today, Porton Pharma Solutions Ltd(300363) announced that company received $681 million cdmo service order from Pfizer’s company. According to today’s US dollar RMB central parity of 6.3681, this order is about 4.337 billion yuan .
It is worth noting that the performance pre increase announcement previously released by Porton Pharma Solutions Ltd(300363) disclosed that it is expected to achieve an operating revenue of 3.004 billion yuan to 3.108 billion yuan in 2021. Obviously, This large order far exceeds Porton Pharma Solutions Ltd(300363) last year’s revenue .
According to the announcement released by Porton Pharma Solutions Ltd(300363) , Pfizer’s products ordered by the company show an upward trend year by year.
The main business of Porton Pharma Solutions Ltd(300363) is chemical raw material cdmo, chemical agent cdmo and biological cdmo.
It is reported that Suzhou boten biology is a cdmo platform for cell gene therapy under Porton Pharma Solutions Ltd(300363) .
Porton Pharma Solutions Ltd(300363) in January, the company said on the interactive easy that as a service platform for cdmo drug development and production, the company has served more than 500 customers at home and abroad.
According to Southwest Securities Co.Ltd(600369) combing the capacity construction of China’s cdmo enterprises, Hequan pharmaceutical, Asymchem Laboratories (Tianjin) Co.Ltd(002821) and Zhejiang Jiuzhou Pharmaceutical Co.Ltd(603456) are listed together with Porton Pharma Solutions Ltd(300363) .
Porton Pharma Solutions Ltd(300363) the performance forecast was released on January 16. It is estimated that the net profit attributable to the parent company in 2021 will be 500 million yuan to 532 million yuan, with a year-on-year increase of 54% to 64%.
According to the research report recently released by Cinda securities, in 2021, Porton Pharma Solutions Ltd(300363) new business made many breakthroughs. In the third quarter, the company not only served 11 cdmo customers of gene cell therapy, but also reached strategic cooperation with five biotech companies. in addition, there are 12 cdmo business service customers. As for Porton Pharma Solutions Ltd(300363) reaching strategic cooperation with Dannuo pharmaceutical to jointly explore and establish an integrated service model of “API + Preparation”, Cinda Securities believes that the project is expected to become the support point for the company’s long-term development .
However, Huaxi Securities Co.Ltd(002926) Cui Wenliang and others said in the research report released on January 16, in 2021, the company continued to promote the capacity-building of cell and gene cdmo business and preparation cdmo, and the loss of new business was about 100 million yuan .
In the research report released on January 17, Lin Xiaowei said that the Q4 performance of Porton Pharma Solutions Ltd(300363) 2021 exceeded market expectations. According to the profit forecast and valuation calculation, it is expected that the year-on-year growth rate of net profit in 2022 will be 65.83% but the year-on-year growth rate of net profit in 2023 will drop sharply to only 24.62% .
According to the analysis of insiders, in the context of the “gold rush” of innovative drugs, the market share of CXO, especially cdmo, which plays the role of “water seller”, is accelerating. In the past 10-20 years, they have been increasingly recognized by customers in terms of cost control, technical capacity, delivery experience, stable quality and safe production, making great breakthroughs in capital expenditure, order growth and product structure. With the emergence of new technologies such as cell / gene therapy, cro / cdmo is likely to be upgraded iteratively following the cycle of R & D and innovation .
However, there is another voice of decline in the current market, some analysts said that according to the current crazy expansion speed of CXO head companies and the current situation of crazy transformation of raw material enterprises into cdmo, there is no so-called slow bull, which will greatly surpass the market expectation and complete the high business cycle . This has also been interpreted in the expansion of silicon wafer, lithium ore, pork and other industries.
